Reboxetine

• Description:

  Reboxetine is an orally active, potent and selective noradrenaline uptake blocker. Reboxetine can be used for antidepressant research[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/reboxetine.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CCOC1=CC=CC=C1O[C@@H]([C@@]2([H])CNCCO2)C3=CC=CC=C3

• Molecular Formula:

  C19H23NO3

• Molecular Weight:

  313.39

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

• References & Citations:

  [1]Dostert P, et al. Reboxetine prevents the tranylcypromine-induced increase in tyramine levels in rat heart. J Neural Transm Suppl. 1994;41:149-53.|[2]Erik H. F. Wong, Saeeduddin Ahmed, et al. Highly selective norepinephrine reuptake inhibitors and methods of using the same. WO2001001973A2 |[3]Herman BD, Fleishaker JC, Brown MT. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. Clin Pharmacol Ther. 1999 Oct;66 (4) :374-9.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  71620-89-8